Study on methoxymorpholino doxorubicin infusion in cancer patients
Author Information
Author(s): Fokkema E, Verweij J, van Oosterom A T, Uges D R A, Spinelli R, Valota O, de Vries E G E, Groen H J M
Primary Institution: University Hospital Groningen
Hypothesis
The study aimed to assess the feasibility, pharmacokinetics, and toxicity of methoxymorpholino doxorubicin administered as a 3-hour intravenous infusion once every 4 weeks.
Conclusion
Prolongation of MMRDX infusion to 3 hours does not improve the toxicity profile compared to bolus administration.
Supporting Evidence
- Fourteen patients received 37 cycles of MMRDX.
- Common toxicity criteria grade III/IV nausea and vomiting were observed in some cycles.
- One patient died with neutropenic fever.
Takeaway
Doctors tested a new way to give a cancer drug, but it didn't make the drug safer or better at fighting cancer.
Methodology
Patients received methoxymorpholino doxorubicin as a 3-hour infusion every 4 weeks, with varying doses.
Limitations
No tumor responses were observed, and the study had a small sample size.
Participant Demographics
Patients had intrinsically anthracycline-resistant tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website